Month: December 2025

ProVen Growth and Income VCT plc  Director/PDMR Shareholding 19 December 2025 ProVen Growth and Income VCT plc (the ”Company”) hereby announces that on 19 December 2025, certain directors, and their closely associated persons, purchased ordinary shares of 1.6187 pence each in the Company. This notification relates to transactions notified in accordance with the Market Abuse Regulation, further details of which are set out below. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Natasha Isobel Christie-Miller 2 Reason for the notification a) Position/status Non-Executive Director b) Initial notification/ Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name ProVen Growth and Income VCT plc b) LEI 213800K1RM776QM8XG84 4 Details...

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 20169 DKT 03/03/26 I 0 0 – – –98 20243 DKT 02/06/26 II 0 0 – – –Total 0 0      

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, ICELAND & TEL AVIV, ISRAEL & PARSIPPANY, NJ (December 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the...

Pursuant to section 30 of the Danish Capital Markets Act, Solar A/S hereby announces that Nordea Funds Ltd. has informed Solar that following its sale of shares on 17 December 2025, Nordea Funds’ holding of Solar B shares now totals 78,788,600 shares at DKK 100, corresponding to 4.96% of the voting rights. ContactsCEO Jens Andersen – tel. +45 79 30 02 01CFO Michael H. Jeppesen – tel. +45 79 30 02 62IR Director Dennis Callesen – tel. +45 29 92 18 11Facts about Solar Solar is a leading European sourcing and services company mainly within electrical, heating and plumbing, ventilation and climate and energy solutions. Our core business centres on product sourcing, value-adding services and optimisation of our customers’ businesses. We facilitate efficiency improvement and provide digital tools that turn our customers into...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstancesREYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth...

Notice to convene the Annual General Meeting on 21 January 2026 – RIAS A/SAttachmentNotice to Convene the Annual General Meeting 21_01_2026

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : December 19th, 2025Issuer Name Issuer code Transactiondate ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired PlatformCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 19.12.2025 FR001400AJ45 354 772 28,1871 euros Over-the-counterIssuer Name Issuer code PSIName Issuer Code Transaction date   ISIN Code Unit Price Currency Quantity bought Platform Transaction reference number Buyback objectiveCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 BNP PARIBAS R0MUWSFPU8MPRO8K5P83 19.12.2025 ...

Sanoma Corporation, Stock Exchange Release, 19 December 2025 at 9:30 a.m. EET Deadline for shareholders’ requests on the 2026 AGM agenda extended As announced on 9 September 2025, Sanoma Corporation’s Annual General Meeting (AGM) 2026 is planned to be held on Thursday, 7 May 2026 in Helsinki. The Board of Directors will summon the AGM at the end of March 2026. A shareholder may request that a matter falling under the authority of the General Meeting of Shareholders shall be placed on the agenda of the AGM. To this effect, a written request should be sent to the Board of Directors. Deadline for sending such request has now been extended to Wednesday, 25 February 2026 (earlier 14 January 2026). Additional information Kaisa Uurasmaa, Head of Investor Relations and Sustainability, tel. +358 40 560 5601 Sanoma Sanoma is an innovative and agile...

The INVL Baltic Sea Growth Fund, the leading private equity fund in the Baltics, has sold its entire stake in the MBL Group to the private equity investor MidEuropa. MBL is a leading European contract development and manufacturing organisation (CDMO) for assisted mobility, rehabilitation and aged-care equipment. The founding Lauritsen family has reinvested a significant amount, and Martin Lauritsen will continue to lead the company as CEO, the transaction participants announced. The exit, the second for the INVL Baltic Sea Growth Fund, already enables full repayment of the fund to investors. Nerijus Drobavičius, a Partner at the INVL Baltic Sea Growth Fund, commented: “We invested in MBL back in mid-2020, during the first Covid wave, as we saw large potential in the company. We have been excited to see the company’s EBITDA almost triple...